Enliven Therapeutics (ELVN)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Precision Oncologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 16/100 (LOW), 122.6 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 19.41% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial
- Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia
- Enliven Therapeutics to Present at Upcoming Investor Conferences
- Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
- Enliven Therapeutics (ELVN) Stock Looks Overvalued As Returns Surge But Book Value Lags
- What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%
- What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally
- Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Phase 1 study of KHK2455, a long-acting, potent and selective IDO1 inhibitor, in combination with avelumab in patients with locally advanced or metastatic urothelial carcinoma. — J Immunother Cancer 2026 Sep 21 PMID 42767768
- Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors. — J Immunother Cancer 2026 Sep 7 PMID 42705861
- Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial. — Leukemia 2026 Sep PMID 42498834
- Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results. — Leukemia 2026 Sep PMID 42463944
- Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA. — Am J Hematol 2026 Sep PMID 42393840
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Enliven Therapeutics.
Full ELVN Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.